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Objectives Maintenance of endothelial homeostasis may prevent the development of cardiac allograft vasculopathy (CAV).
This study investigated whether biomarkers related to endothelial injury and endothelial repair discriminate be-
tween CAV-negative and CAV-positive heart transplant recipients.
Background CAV is the most important determinant of cardiac allograft survival and a major cause of death after heart
transplantation.
Methods Fifty-two patients undergoing coronary angiography between 5 and 15 years after heart transplantation were
recruited in this study. Flow cytometry was applied to quantify endothelial progenitor cells (EPCs), circulating
endothelial cells (CECs), and endothelial microparticles. Cell culture was used for quantification of circulating
EPC number and hematopoietic progenitor cell number and for analysis of EPC function.
Results The EPC number and function did not differ between CAV-negative and CAV-positive patients. In univariable mod-
els, age, creatinine, steroid dose, granulocyte colony–forming units, apoptotic CECs, and apoptotic endothelial
microparticles discriminated between CAV-positive and CAV-negative patients. The logistic regression model con-
taining apoptotic CECs and apoptotic endothelial microparticles as independent predictors provided high discrim-
ination between CAV-positive and CAV-negative patients (C-statistic 0.812; 95% confidence interval: 0.692 to
0.932). In a logistic regression model with age and creatinine as covariates, apoptotic CECs (p  0.0112) and
apoptotic endothelial microparticles (p  0.0141) were independent predictors (C-statistic 0.855; 95% confi-
dence interval: 0.756 to 0.953). These 2 biomarkers remained independent predictors when steroid dose was
introduced in the model.
Conclusions The high discriminative ability of apoptotic CECs and apoptotic endothelial microparticles is a solid foundation
for the development of clinical prediction models of CAV. (J Am Coll Cardiol 2012;60:324–31) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.065Cardiac allograft vasculopathy (CAV) in heart transplant
recipients is characterized by the coexistence of diffuse fibro-
muscular intimal hyperplasia and focal atherosclerosis (1,2). It
is largely an immunologic phenomenon that is modified by
nonimmunologic factors. Diffuse concentric lesions of fibro-
muscular intimal hyperplasia develop in the epicardial and the
smaller intramyocardial arteries, whereas focal, eccentric ath-
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(1,2). CAV may lead to late graft failure and is, in addition
to malignancy, the most important cause of death in heart
transplant recipients after the first year (1,3,4).
According to the response to injury concept of CAV,
vascular lesions are considered to be the result of cumulative
endothelial injury by both alloimmune responses and nonallo-
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July 24, 2012:324–31 Biomarkers and Cardiac Allograft Vasculopathyimmune insults (1,5). T-cell alloimmunity, antibody-mediated
immune attack, and nonimmune factors induce endothelial
activation or endothelial cell death. This may initiate a
cascade of events, including platelet activation and inflam-
mation with infiltration of predominantly macrophages and
T cells in the vessel wall followed by smooth muscle cell
activation, migration, and proliferation.
To maintain endothelial homeostasis, endothelial cell
death should be balanced by endothelial repair mechanisms.
After endothelial cell detachment induced by prolonged
activation of endothelial cells or immunologic injury, endo-
thelial cells can be detected in the peripheral blood as viable
circulating endothelial cells (CECs) or as apoptotic CECs
(6,7). In addition to CECs, endothelial microparticles
constitute another biomarker of endothelial injury. Endo-
thelial microparticles arise from exocytic budding after
endothelial cell activation or apoptosis (8–10). The process
of endothelial injury is counteracted by endothelial repair
mechanisms. Increased endothelial progenitor cell (EPC)
number and function may enhance endothelial repair in
allografts directly via increased EPC incorporation
(“building block” role) or indirectly via production of
growth factors (paracrine role). EPCs that promote re-
endothelialization in a paracrine way have been named
proangiogenic progenitor cells (11) and are in fact hematopoi-
etic lineage cells. Cells of the hematopoietic lineage may be
mobilized from the bone marrow and are entrapped in
peripheral tissues, where they release angiogenic signals
(12). A comprehensive analysis of endothelial repair mech-
anisms should therefore not be restricted to classic EPC
quantifications but also entail enumeration of hematopoietic
progenitor cells (HPCs).
Clinical prediction models of CAV are currently not
available and may be useful for noninvasive diagnostic and
prognostic purposes. Our hypothesis was that biomarkers of
endothelial homeostasis would constitute a solid foundation
for the development of such clinical prediction models.
Therefore, the objective of the current study was to evaluate
whether biomarkers related to endothelial repair (EPC
number, EPC function, HPC number) and to endothelial
injury ([apoptotic] CECs, [apoptotic] endothelial micropar-
ticles) discriminate between CAV-negative and CAV-
positive heart transplant recipients.
Methods
Patient population and CAV grading. Fifty-two patients
undergoing coronary angiography in the framework of
their routine follow-up between 5 and 15 years after heart
transplantation were recruited in this cross-sectional
study. Heart transplant recipients with prior congenital
heart disease and patients who underwent retransplanta-
tion were excluded. The study was approved by the
Ethics Committee of the University Hospital Gasthuis-
berg, and written informed consent was obtained from all
participating subjects. To establish reference values ofselected biomarkers, 25 healthy
control subjects age 43.2  2.0
years were selected.
Coronary angiograms were an-
alyzed by 3 transplant cardiologists
(A.C., W.D., and J.V.C.). CAV
was graded according to the Inter-
national Society for Heart and
Lung Transplantation working
formulation of a standardized no-
menclature for CAV-2010 (13).
Patients with CAV1, CAV2, and
CAV3 were pooled and constitute
he CAV-positive group. Patients
ith CAV0, defined as no detectable angiographic lesion,
constitute the CAV-negative group.
Endomyocardial biopsies were scored for acute rejection
according to Billingham et al. (14), and mean biopsy score
of all biopsies in the first year was calculated according to
Mehra et al. (15).
Quantification of EPC number and EPC function based
on cell culture assays. Peripheral blood was anticoagulated
with sodium heparin, and mononuclear cells were isolated
from 18 ml of blood by density gradient centrifugation with
Ficoll-PAQUE PLUS (Stem Cell Technologies, Grenoble,
France), according to the manufacturer’s protocol. Mono-
nuclear cell count was determined using a Nucleocounter
(Chemometec, Allerød, Denmark).
Cultivation of early EPCs was performed as described by
Vasa et al. (16). Briefly, mononuclear cells were plated onto
fibronectin-coated 24-well culture dishes (BD Biosciences,
San Jose, California) in endothelial basal medium (Cam-
brex, East Rutherford, New Jersey) supplemented with
endothelial growth medium SingleQuots (Cambrex) and
20% fetal bovine serum (Invitrogen, Carlsbad, California) at
a density of 4  106 cells/well. After 4 days of incubation,
EPCs were quantified as the number of 1,1=-dioctadecyl-
3,3,3=,3=-tetramethylindocarbocyanine-labeled acetylated
LDL (Dil-acLDL) FITC-labeled Ulex europaeus agglutinin-I
lectin double-positive cells per microscopy field. Experiments
were performed in duplicate.
Migration of cultured early EPCs was studied as previ-
ously described (16,17). Stromal-derived factor-1 (100 ng/ml;
&D Systems, Inc., Minneapolis, Minnesota) was added in
he lower chamber.
PC culture assay. Cultivation of HPCs was performed
sing semisolid methylcellulose– based medium (Meth-
cult H4434 Classic; Stem Cell Technologies), according
o the manufacturer’s protocol. Briefly, peripheral blood
ononuclear cells (1  105 cells/dish and 2  105
cells/dish) were seeded in 35-mm culture dishes (Stem
Cell Technologies) in 2 ml of Methocult medium (Stem
Cell Technologies). After 14 days of incubation, ery-
throid burst–forming units; erythroid colony–forming
units; granulocyte colony–forming units; macrophage
Abbreviations
and Acronyms
CAV  cardiac allograft
vasculopathy
CEC  circulating
endothelial cell0
EPC  endothelial
progenitor cell
HPC  hematopoietic
progenitor cell
VEGFR  vascular
endothelial growth factor
receptorcolony–forming units; granulocyte, macrophage colony–
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megakaryocyte colony–forming units were enumerated
using an inverted microscope.
Quantification of the number of circulating EPCs, en-
dothelial cells, and endothelial microparticles by flow
cytometry. EPC concentration was also measured by
fluorescence-activated cell sorting analysis of the circulating
number of CD34 vascular endothelial growth factor recep-
tor (VEGFR)-2 double-positive cells, as described previ-
ously (18,19).
CECs were identified as CD45 CD31bright VEGFR-2
mononuclear cells (20). Annexin V staining distinguishes
between viable and apoptotic CECs (21). Samples were
acquired on a high flow rate (120 l/min) for 3 min using
a BD FACSCantoII flow cytometer and BD FACSDIVA
software version 1.2.6 (BD Biosciences), with a minimum
detection number of 100,000 events within the mononu-
clear cell gate.
Blood that was used for microparticle quantification by
flow cytometry was anticoagulated with sodium citrate. To
exclude microparticles derived from nonendothelial cells,
mainly platelets, endothelial microparticles were defined as
CD144 (VE-cadherin) CD42a microparticles (22). An-
exin V binding was used to discriminate between apoptotic
nd nonapoptotic microparticles. Apoptotic endothelial mi-
roparticles were defined as Annexin V CD144 CD42a
microparticles (22).
Statistical analysis. Clinical and biochemical parameters
and biomarkers (EPC concentration, EPC function, HPC
number, CEC concentration, and number of endothelial
microparticles) were compared between CAV-negative and
CAV-positive patients using Instat 3 (GraphPad Software,
Inc., San Diego, California). Continuous variables were
summarized by means, standard error of the mean, and
sample size, and were compared by an unpaired t test.
ecause the distribution of the concentration of CECs is
eavily right-skewed, a transformation (natural logarithm)
as applied and geometric means were compared. The
isher exact test was used to compare categoric data
etween patients with and without CAV. Logistic regres-
ion analysis was performed by SAS software, version 9.2
SAS Institute Inc., Cary, North Carolina). The discrimi-
ative ability is quantified using the concordance statistic
C-statistic), which is equal to the area under the receiver-
perating characteristic curve. A natural logarithm transfor-
ation of CEC data was also applied for logistic regres-
ion analysis. A p value 0.05 was considered statistically
ignificant.
esults
linical characteristics of heart transplant recipients
ith and without CAV. The clinical characteristics of
eart transplant recipients are shown in Table 1. Patients
ith CAV were significantly older at the time of inclusionn the study. There was a trend for a greater donor age inpatients with CAV, whereas the difference in time after
transplantation did not reach statistical significance. Donor
age correlated moderately with the age of the recipient at
the time of transplantation (r  0.368; p  0.01). The age
of the transplanted heart (sum of donor age and time after
heart transplantation) was significantly greater in CAV-
positive patients (Table 1). The proportion of patients with
ischemic heart disease did not differ between both groups.
Acute rejection episodes (grade 3A) were not significantly
more frequent in the CAV group than in the non-CAV
group (Table 1). The average rejection score of biopsies in
the first year also was not significantly different between
patients without CAV (0.484  0.057) and patients with
CAV (0.546  0.057). Creatinine levels were significantly
greater in the CAV group than in the non-CAV group
(Table 1). Low-density lipoprotein cholesterol in the CAV
group was 16% (p  0.05) less than in the non-CAV group
(Table 1), which reflects a policy to switch to more potent
statins once a diagnosis of angiographic CAV is made. The
percentage of patients receiving steroids was 3.5-fold (p 
.01) greater in patients with CAV compared with patients
ithout CAV.
PC number and function do not significantly differ
etween CAV-negative and CAV-positive heart transplant
ecipients. EPCs were quantified as the number of Dil-acLDL
nd FITC-labeled UEA-1 lectin double-positive cells after
days of ex vivo culture or as the number of circulating
D34 VEGFR-2 cells. Gating strategy and flow cytom-
etry analysis of EPCs are illustrated in Online Figure 1. The
number of FITC-labeled UEA-1 lectin double-positive
cells was 49% (p 0.0001) less in transplant recipients than
in healthy controls (Online Fig. 2A) but did not differ
between patients without CAV and with CAV (Table 2).
The number of circulating CD34 VEGFR-2 cells was
imilar in healthy controls and transplant recipients (Online
ig. 2B) and between CAV-negative and CAV-positive
ransplant recipients (Table 2).
EPC migration induced by stromal-derived factor-1
(100 ng/ml) was 31% (p  0.05) less in patients than in
healthy controls (Online Fig. 2C). No difference in EPC
migration was observed between CAV-negative and CAV-
positive patients (Table 2), indicating similar EPC function.
Granulocyte colony–forming units are significantly less
in the peripheral blood of patients with CAV than in
patients without CAV. Online Figure 3 compares HPC
number between healthy controls and transplant recipients.
Erythroid burst–forming units; granulocyte, macrophage
colony–forming units; macrophage colony–forming units;
and granulocyte colony–forming units were significantly less
in transplant recipients than in healthy controls, whereas no
significant differences were observed for erythroid colony–
forming units and granulocyte, erythrocyte, macrophage,
megakaryocyte colony–forming units (Online Fig. 3). The
number of granulocyte colony–forming units was reduced
by 59% (p  0.05) in patients with CAV compared with
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observed in other types of colonies (Table 2).
Circulating apoptotic endothelial cells are significantly
greater in patients with CAV than in patients without
CAV. The geometric mean of the concentration of circu-
lating endothelial (CD45 CD31bright VEGFR-2) cells,
apoptotic endothelial (CD45 CD31bright VEGFR-2 An-
nexin V positive) cells, and viable endothelial (CD45
CD31bright VEGFR-2 Annexin V negative) cells was
ncreased by 1.7-fold (p  0.062), 1.5-fold (p  NS), and
.8-fold (p  0.053), respectively, in transplant recipients
ompared with healthy controls (Online Fig. 4). The
eometric mean of total, apoptotic, and viable endothelial
ells was 2.0-fold (p  0.063), 2.6-fold (p  0.01), and
Patient Characteristics, Clinical Laboratory ParaHypolipidemic Therapy in CAV-Negative and CAVTable 1 Pa ient Characteristics, Clinical LaHypolipidemic Therapy in CAV-Nega
Patie
Age at inclusion in the study (yrs)
Sex
Male
Female
Donor age (yrs)
Time after heart transplantation (yrs)
Age of the transplanted heart (yrs)
Sex mismatch graft
Acute rejection episodes (grade 3A or 3A)
Ischemic heart disease
Current smoker
Hypertension
Diabetes
Body mass index (kg/m2)
Platelet count (109/l)
Leukocyte count (109/l)
Monocyte count (109/l) 0
Lymphocyte count (109/l)
Neutrophil count (109/l)
Creatinine (mg/dl)
Cholesterol (mg/dl)
Triglycerides (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
Statins
Cyclosporine
Tacrolimus
Everolimus
Azathioprine
MMF
Steroid
Cyclosporine  azathioprine
Cyclosporine  MMF
Tacrolimus  MMF
Everolimus  MMF
Tacrolimus  everolimus
Values are mean  SEM or %.
CAV  cardiac allograft vasculopathy; LDL  low-density lipoprotei
SEM  standard error of the mean..9-fold (p  NS) greater, respectively, in patients withAV compared with patients without CAV (Table 3).
ating strategy and flow cytometry analysis of apoptotic
ECs are illustrated in Online Figure 5.
irculating apoptotic endothelial microparticles are sig-
ificantly greater in patients with CAV than in patients
ithout CAV. The concentration of circulating endothelial
CD42a CD144) microparticles, apoptotic endothelial
(CD42a CD144 Annexin V positive) microparticles, and
iable endothelial (CD42a CD144 Annexin V negative)
microparticles was 2.6-fold (p  0.0001), 2.0-fold (p 
0.001), and 2.6-fold (p  0.0001) greater, respectively, in
transplant recipients compared with healthy controls (On-
line Fig. 6). The concentration of total, apoptotic, and
viable endothelial microparticles was 1.8-fold (p  0.05),
rs, and Immunosuppressive anditive Heart Tra splant Recipie tsory Parameters, and Immunosuppressive and
nd CAV-Positive Heart Transplant Recipients
ithout CAV
22)
Patients With CAV
(n  30) p Value
3.2 64.9 2.1 0.0212
1.00
8 80.0
2 20.0
2.9 40.8 2.4 0.0699
0.58 10.9 0.8 0.118
3.0 51.7 2.3 0.0298
6 20.0 0.716
6 10.0 0.689
4 50.0 0.402
6 0 0.0697
9 100 0.174
2 36.7 0.217
0.8 25.5 0.5 0.264
16 217 12 0.421
0.33 6.87 0.24 0.764
0.048 0.313 0.039 0.704
0.13 1.28 0.12 0.793
0.32 3.78 0.36 0.170
0.10 1.60 0.08 0.0134
8 156 6 0.211
7 125 12 0.244
2.9 54.2 3.4 0.487
5.7 77.1 4.0 0.0436
5 100 0.423
8 23.3 0.540
6 70.0 0.766
55 20.0 0.216
10 13.3 1.00
4 60.0 0.0622
2 63.3 0.0018
09 0 0.174
7 13.3 0.468
1 40.0 0.160
55 16.7 0.225
10.0 0.253
 high-density lipoprotein; MMF  mycophenolate mofetil;mete-Posborat
tive a
nts W
(n 
56.3
81.
18.
33.8
9.35
43.2
13.
13.
36.
13.
90.
18.
26.6
232
6.81
.334
1.24
3.12
1.32
168
108
55.0
91.6
95.
31.
63.
4.
9.
86.
18.
9.
22.
59.
4.
02.0-fold (p  0.01), and 1.7-fold (p  0.05) greater,
1ietic pro
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without CAV (Table 3). Gating strategy and flow cytometry
analysis of apoptotic endothelial microparticles are illus-
trated in Online Figure 7.
Discrimination between CAV-positive and CAV-negative
transplant recipients based on logistic regression and
receiver-operating characteristic analysis. Table 4 sum-
marizes C-statistic values of univariable models. The odds
ratio per standard deviation increase of apoptotic CECs
(natural logarithm transformed) and apoptotic endothelial
microparticles was 2.32 (95% CI: 1.14 to 4.71; p  0.0196)
and 3.24 (95% CI: 1.17 to 8.96; p  0.0234), respectively.
The receiver-operating characteristic curve for the logistic
regression function containing apoptotic CECs and apopto-
tic endothelial microparticles as independent predictors is
shown in Figure 1. The C-statistic was 0.812 (95% CI:
0.692 to 0.932).
In a logistic regression model with recipient age and
creatinine as covariates, apoptotic CECs and apoptotic
endothelial microparticles added significant information
(chi-square  18.4; df  2; p  0.0001) and were both
independent predictors (Table 5). The C-statistic corre-
sponding to this model was 0.855 (95% CI: 0.756 to 0.953).
When recipient age in these models was substituted by time
Comparison of EPC Number, EPC Function, andHPC Number Between CAV-Negative and CAV-PTable 2 Comparison of EPC Number, EPC FHPC Number Between CAV-Negativ
Patients
(n
Dil-acLDL/lectin cells (n/mm2) 13.
CD34 VEGFR-2 cells (n/l blood) 2.0
Migrated cells (n/mm2) 38.
CFU-E (number per 2  105 MNC) 5.2
BFU-E (number per 2  105 MNC) 17.
CFU-GEMM (number per 2  105 MNC) 1.1
CFU-GM (number per 2  105 MNC) 3.9
CFU-M (number per 2  105 MNC) 0.75
CFU-G (number per 2  105 MNC) 0.52
Values are mean  SEM.
BFU-E  erythroid burst–forming unit; CAV  cardiac allograft va
colony–forming unit; CFU-GEMM granulocyte, erythrocyte, macropha
colony–forming unit; CFU-M  macrophage colony–forming unit; D
acetylated LDL; EPC  endothelial progenitor cell; HPC  hematopo
mean; VEGFR-2  vascular endothelial growth factor receptor-2.
Comparison of CEC and Circulating EndothelialBetween CAV-Negative and CAV-Positive PatienTable 3 Comp r son of CEC and Circul t ngBetween CAV-Negative and CAV-Po
Patients Wit
(n  2
Total CECs (ln [n/l blood]) 0.268
Apoptotic CECs (ln [n/l blood]) 2.07
Viable CECs (ln [n/l blood]) 0.502
Total CEMPs (n/l plasma) 0.0662
Apoptotic CEMPs (n/l plasma) 0.00650
Viable CEMPs (n/l plasma) 0.0597
Values are mean  SEM.
CAV  cardiac allograft vasculopathy; CEC  circulating endothelial cell; C
SEM  standard error of the mean.after heart transplantation or age of the transplanted heart,
results were essentially unaltered (data not shown).
When steroid dose was introduced in the model, apoptotic
CECs and apoptotic endothelial microparticles remained in-
dependent predictors (data not shown). The C-statistic corre-
sponding to this model was 0.926 (95% CI: 0.851 to 1.00).
There was significant added value of introduction of apoptotic
CECs together with endothelial apoptotic microparticles in
the model with age, creatinine, and steroid dose (chi-square
6.3; df  2; p  0.0003).
Discussion
This is the first study to demonstrate that apoptotic CECs
and apoptotic endothelial microparticles are independent
predictors of CAV and that the combination of these 2
biomarkers has a high discriminative ability between pa-
tients without CAV and with CAV.
Clinical parameters and CAV. A salient finding of the
current study is that steroid use was more prevalent in
CAV-positive patients than in CAV-negative patients. This
is in line with a report of the Stanford group in 2004 (23) in
a population of patients receiving an immunosuppressive
background therapy predominantly comprising cyclosporine
e Patientson, nd
CAV-Positive Patients
ut CAV
)
Patients With CAV
(n  30) p Value
9 14.6 1.8 0.685
46 1.95 0.52 0.875
7 35.1 3.1 0.495
81 5.08 0.81 0.910
1 21.6 2.6 0.180
29 2.08 0.58 0.179
61 3.53 0.49 0.634
157 0.975 0.342 0.554
125 0.217 0.089 0.0147
athy; CFU-E  erythroid colony–forming unit; CFU-G  granulocyte
akaryocyte colony–forming unit; CFU-GM granulocyte, macrophage
L  1,1=-dioctadecyl-3,3,3=,3=-tetramethylindocarbocyanine-labeled
genitor cell; MNC  mononuclear cell; SEM  standard error of the
particlesthelial Microparticles
Patients
AV Patients With CAV
(n  30) p Value
0.429 0.251 0.0627
1.11 0.26 0.0099
0.114 0.256 0.111
0.116 0.018 0.0400
4 0.0128 0.0019 0.0039
0.104 0.017 0.0410ositivuncti
e and
Witho
 22
6 1.
6 0.
4 3.
0 0.
1 2.
8 0.
1 0.
0 0.
3 0.
sculop
ge, meg
il-acLDMicrotsEnd
sitive
hout C
2)
0.266
0.25
0.281
0.0159
0.0008
0.0153EMP  circulating endothelial microparticle; ln  natural logarithm;
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continuation of steroids after severe acute rejection episodes
in the first year, because the proportion of patients with
severe acute rejection episodes in the first year was similar in
patients with CAV compared with patients without CAV.
Second, difference of steroid use also cannot be the result of
tailoring of therapy according to renal function because
creatinine levels were not different between steroid users and
nonsteroid users (data not shown). On the other hand, the
time after heart transplantation was significantly (p  0.05)
longer in steroid users (11.6  0.9 years) compared with
nonsteroid users (9.1 0.5 years). This reflects an evolution
to steroid-free immunosuppressive regimens in patients who
Discrimination Between CAV-Positive andCAV-Negative Transpla t Recipients B sedon Receiver-Operating Characteris ic A alysis
Table 4
Discrimin tion Between CAV-Positive and
CAV-Negative Transplant Recipients Based
on Receiver-Operating Characteristic Analysis
C-Statistic (95% CI)
Age 0.689 (0.537–0.842)
Creatinine 0.703 (0.552–0.854)
LDL cholesterol 0.660 (0.507–0.813)
Steroid dose 0.758 (0.642–0.873)
CFU-G 0.681 (0.547–0.815)
Apoptotic CECs 0.709 (0.567–0.851)
Apoptotic endothelial microparticles 0.697 (0.554–0.840)
The C-statistic corresponds to the area under the receiver-operating characteristic curve.
CAV  cardiac allograft vasculopathy; CEC  circulating endothelial cell; CFU-G  granulocyte
olony–forming unit; CI  confidence interval; LDL  low-density lipoprotein.
Figure 1
Receiver-Operating Characteristic Curve for the
Logistic Regression Model With Apoptotic CECs
and Apoptotic Endothelial Microparticles as Predictors
This receiver-operating characteristic curve illustrates the discriminative ability
of the 2 new biomarkers investigated in the current study. The area under this
curve is equal to the C-statistic. AUC  area under the curve; CEC  circulat-
ing endothelial cell; CI  confidence interval.more recently underwent transplantation. However, steroid
use was also predictive of the presence of CAV in models in
which the time after transplantation was introduced as a
covariate. Therefore, we cannot exclude the possibility that
continued steroid use plays a causative role in the develop-
ment of CAV.
Impaired renal function was an independent predictor of
the presence of CAV. The natural history of renal function
after heart transplantation is characterized by a decline in
renal function (24). Age, pre-transplant glomerular filtra-
tion rate, pre-transplant diabetes, and pre-transplant hyper-
tension are important risk factors for a decrement of renal
function (24). Nephrotoxicity of calcineurin inhibitors is
largely responsible for the progressive development of renal
dysfunction (25,26). Our results are in line with those of
Schober et al. (27). However, impaired renal function was
not a predictor in a study with angiographic follow-up
limited to 4 years (28).
The observation that time after transplantation does not
predict the CAV status may seem illogical. However, the
recruitment of patients in the current study was restricted to
heart transplant recipients between 5 and 15 years after
transplantation undergoing coronary angiography during
follow-up. Because of this selection procedure, time after
transplantation tends to be similar in the CAV-positive and
CAV-negative patients.
Biomarkers of endothelial repair and CAV. We did not
observe a difference between CAV-positive and CAV-
negative patients in the number of EPCs quantified as the
number of CD34 VEGFR-2 cells by flow cytometry
analysis or as the number of Dil-acLDL and FITC-labeled
UEA-1 lectin double-positive cells after 4 days of ex vivo
culture. Furthermore, EPC function was similar in patients
with CAV and without CAV. In contrast, Simper and
colleagues (29) observed that the number of EPC colony–
forming units (late outgrowth EPCs) appearing over a
6-week culture period was significantly less in 8 patients
with CAV compared with 7 patients without CAV. How-
ever, our results are in line with those of Thomas et al. (30)
and Schober et al. (27), who quantified EPC count as the
number of CD34 VEGFR-2 cells. Schober et al. (27)
demonstrated that the number of CD34 CD140b
smooth muscle progenitor cells is independently associated
Logistic Regression Model for Prediction of CAVTable 5 Logistic Regression Model for Prediction of CAV
OR (95% CI) p Value
Age (yrs) 1.38 (0.66–2.88) 0.399
Creatinine (mg/dl) 3.50 (1.27–9.66) 0.0158
Apoptotic CECs (ln number/l) 4.34 (1.40–13.5) 0.0112
Apoptotic endothelial microparticles
(number/100 l)
5.30 (1.40–20.0) 0.0141
Odds ratios (OR) are expressed per standard deviation increase.
CAV  cardiac allograft vasculopathy; CEC  circulating endothelial cell; CI  confidence
interval; ln  natural logarithm.with the presence of CAV.
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Biomarkers and Cardiac Allograft Vasculopathy July 24, 2012:324–31The EPC number based on ex vivo culture assay was
lower and EPC function was impaired in transplant recip-
ients compared with healthy controls. Different classes of
immunosuppressive drugs may affect EPC biology (31,32).
Therefore, the lack of discriminative ability of EPC number
and EPC function to detect the presence of CAV may be
related to a generalized impairment of these parameters in
heart transplant recipients receiving different classes of
immunosuppressive drugs. In contrast, in a murine model of
transplant vasculopathy without immunosuppression, in-
creased EPC number and enhanced EPC function attenu-
ated progression of the disease (33,34).
Because the term EPC is used in a very broad sense in the
literature, EPCs encompass different categories of cells with
different phenotypic and functional properties that affect
neovascularization and re-endothelialization. A salient ob-
servation in the current study is that EPC number defined
as CD34 VEGFR-2 cells did not differ between healthy
ontrols and transplant recipients in contrast to EPC
umber determined by ex vivo cell culture. This basically
eflects that the same term is used for entirely different
ategories of cells. Many so-called “EPCs” are in fact
ematopoietic lineage cells. HPCs may differentiate into
roangiogenic cells (12) and may promote neovasculariza-
ion and endothelial repair in a paracrine way. HPC culture
ssays showed a significantly lower number of granulocyte
olony–forming units in the peripheral blood of CAV-
ositive compared with CAV-negative patients. However,
n multivariate logistic regression, the number of granulo-
yte colony–forming units was not an independent predictor
f the presence of CAV (data not shown). Taken together,
iomarkers of endothelial repair that were evaluated in the
urrent study are not suited for clinical prediction models of
AV. However, we cannot exclude that other assays of
ndothelial repair discriminate between CAV-negative and
AV-positive patients in multivariable models.
iomarkers of endothelial injury and CAV. The concen-
ration of apoptotic endothelial microparticles and apoptotic
ECs was significantly different between CAV-positive and
AV-negative patients. As indicated by the C-statistic
alue of 0.812, the logistic regression model combining
hese 2 biomarkers provides high discriminative ability
etween CAV-positive and CAV-negative patients.
In several logistic regression models, the introduction of
poptotic CECs and apoptotic endothelial microparticles
onsistently resulted in added value, indicating that these
iomarkers are robust independent predictors. Whereas the
nal model in the current study is restricted to age,
reatinine, apoptotic CECs, and apoptotic endothelial mi-
roparticles, the latter 2 parameters remain significant pre-
ictors in models with creatinine and steroid dose. Of note,
he discriminative ability of these 2 biomarkers was also
reserved in models in which recipient age was replaced by
ime after transplantation or age of the transplanted heart.
tudy limitations. Because the number of subjects in the
urrent study is limited to 22 CAV-negative patients and 30AV-positive patients, models with more than 3 predictors
hould be interpreted with caution (35). Inclusion of too
any predictors leads to overfitting of the data and
-indices are overestimated (35). However, the additional
odels strongly suggest that the discriminative ability of
poptotic endothelial microparticles and apoptotic CECs is
ot affected by potential confounders such as age, renal
unction, and steroid dose.
Annexin V positivity, corresponding to phosphatidylser-
ne externalization, should be interpreted with caution. It is
lready positive in an early and potentially reversible stage of
poptosis (36,37) and is not entirely specific for apoptosis
38,39). However, these issues do not undermine the
iscriminative ability of Annexin V positive categories that
ere evaluated in the current study.
uture studies. The high discriminative ability of apopto-
ic CECs and apoptotic endothelial microparticles provides
solid foundation for the further development of clinical
rediction models of CAV in the framework of prospective
tudies that evaluate CAV by coronary intravascular ultra-
ound. Prospective prediction models may lead to a more
ational and tailored use of coronary angiography and
ntravascular ultrasound that are not without risk. In addi-
ion, risk prediction models may allow quicker intervention
nd may help in the design of new randomized clinical trials
o optimize therapy in heart transplant recipients.
onclusions
poptotic CECs and apoptotic endothelial microparticles
redict the presence of CAV independent of the age of the
ecipient, age of the transplanted heart, creatinine level,
teroid use, and number of granulocyte colony–forming
nits. The results of the current study are compatible with
he hypothesis that endothelial activation and injury are
nvolved in the development of CAV.
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